Swedish Mega-Study scans 1,400 for clues to heart, lung, and liver disease

NCT ID NCT07476703

First seen Mar 21, 2026

Summary

This study is re-examining 1,400 adults in Stockholm to find early signs and risk factors for heart, lung, and liver diseases. Participants will get advanced scans, blood tests, and questionnaires. The goal is to better understand how these diseases develop and how to predict them.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cardiovascular Research Lab, Dept Cardiology, Danderyd University Hospital

    RECRUITING

    Stockholm, 18288, Sweden

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this study could improve early detection and risk prediction for heart, lung, and liver diseases, potentially guiding future prevention strategies.

What could go wrong

This is an observational study, not a treatment trial. It cannot prove cause and effect, and results may not apply to other populations.

Conditions

The condition(s) this trial relates to.

aortic aneurysm Aortic Valve Disease aortic valve disorder chronic obstructive pulmonary disease congenital mitral valve insufficiency and/or stenosis COPD, severe early onset coronary artery disorder Dyslipidemias fatty liver disease heart failure Inflammation lung disorder metabolic dysfunction-associated steatohepatitis metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.